Healthcare Industry News:  PROGRESS study 

Devices Oncology Radiology

 News Release - April 17, 2007

Imaging Diagnostic Systems' CT Laser Mammography Attracts Media Attention at European Congress of Radiology 2007

Study Results Compared CTLM to MR for Detecting Remaining Angiogenesis after Neoadjuvant Therapy

FORT LAUDERDALE, Fla., April 17 (HSMN NewsFeed) -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS ) a pioneer in laser optical breast imaging systems, attracted media attention at the European Congress of Radiology (ECR) 2007, March 9-13 in Vienna, Austria, with the results of a comparison study of CT Laser Mammography (CTLM) and MR. Featured in a poster at the company's exhibit, the results are from a work-in-PROGRESS study conducted by physicians at Catholic University in Rome, Italy. The results compare CTLM to MR for detecting remaining angiogenesis after neoadjuvant therapy and suggest that CTLM may be more sensitive than MR for treatment monitoring.

The study results and CTLM technology were featured in a March 21 article on, a community website of the Institute of Physics in the United Kingdom. The article is featured on the medicalphysicsweb website at . A quick registration with the site is required to view the article.

Deborah O'Brien, IDSI Senior Vice President, commented: "At ECR 2007, we were able to generate commercial and clinical exposure in one of our most important markets. We introduced CTLM and the principles behind our technology to European physicians, members of the media, and other radiologic professionals who were unfamiliar with the clinical and scientific fundamentals. At the same time, we informed attendees who are already familiar with CTLM of our progress and developments. The meeting allowed us to build on the momentum in Europe created by our clients and luminary partners and establish new relationships within the global radiology community."

One of the leading international events in radiology, ECR 2007 attracted over 17,000 attendees from 94 countries.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our corporate website:

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Source: Imaging Diagnostic Systems

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.